Ciphergen has signed a collaborative research agreement with Sanofi-Aventis, extending its existing relationship. The project will concentrate on discovery, validation, and identification of biomarkers for a preclinical drug efficacy study in the field of oncology. Under the terms of the agreement, Ciphergen will analyze samples at one of its Biomarker Discovery Center laboratories using its suite of proteomic solutions. Financial terms were not disclosed.

“We are extremely pleased to be partnering with Sanofi-Aventis, an organization committed to innovation which shares our vision to accelerate and streamline development of new drugs through the early identification of relevant drug efficacy biomarkers,” stated Gail S. Page, president and chief executive officer of Ciphergen. “The partnership allows Sanofi-Aventis access to our expert scientists and latest technologies and is an important addition to our translational proteomics partnerships for drug discovery and development.”